SEATTLE and TULSA, Okla., July 14 /PRNewswire/ — Genelex and Helix
have announced a personalized prescribing strategic alliance to
increase the availability of important new DNA Drug Sensitivity
Tests such as Plavitest™ and Tamoxitest™. These tests
and the GeneMedRx medication management software can save lives and
healthcare dollars by allowing doctors to personalize their
prescribing practices in order to prevent adverse medication
outcomes, including treatment failures and dangerous side
effects.
“Helix’s knowledge and experience make them ideally suited to
expand access to these products and contribute to improving
prescribing safety,” said Howard
Coleman, Genelex Chief Executive Officer.
Helix is concentrating its initial efforts on
Plavitest™ due to the recent FDA boxed warning placed on
Plavix. Recent clinical research demonstrates that
approximately one-third of patients are in varying degrees of
treatment failure and could be at an increased risk of a recurrent
heart attack, stroke or cardiovascular death. Plavitest identifies
these patients so doctors can improve their medication regimen and
chances for successful treatment. Plavix is the second leading
selling prescription drug with over $8
billion in worldwide annual sales.
“We chose Genelex as our laboratory partner because of its
proven track record in delivering DNA Drug Sensitivity Tests and
the advantage of the GeneMedRx interpretive software,” said Lincoln Maxwell, Helix chief executive
officer. GeneMedRx closes the “interpretation gap” by providing
prescribers actionable information to reduce the risk of treatment
failures and adverse reactions based on the genetics and over
‘/>”/>
